In vitro and in vivo antagonism of a g protein-coupled receptor (s1p 3) with a novel blocking monoclonal antibody

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Harris, Greg L ^a,b   Creason, Michael B ^a   Brulte, Greg B ^a   Herr, Deron R ^a,b  

^a Expression Drug Designs LLC   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7H9; RETINA S ANTIGEN; SPHINGOSINE 1 PHOSPHATE 3 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CALCIUM; SIP3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; CALCIUM MOBILIZATION; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SEPSIS; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; IMMUNOLOGY; MALE; METABOLISM; NUDE MOUSE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ADENYLATE CYCLASE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ARRESTIN; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; RECEPTORS, LYSOSPHINGOLIPID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859363534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035129     Document Type: Article

References (55)

1. Maggon K, (2007) Monoclonal antibody "gold rush". Curr Med Chem 14: 1978-1987.
2. Oskouian B, Saba JD, (2004) Death and taxis: what non-mammalian models tell us about sphingosine-1-phosphate. Semin Cell Dev Biol 15: 529-540.
3. Meyer zu Heringdorf D, Liliom K, Schaefer M, Danneberg K, Jaggar JH, et al. (2003) Photolysis of intracellular caged sphingosine-1-phosphate causes Ca2+ mobilization independently of G-protein-coupled receptors. FEBS Lett 554: 443-449.
4. Zhang YH, Vasko MR, Nicol GD, (2006) Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons. J Physiol 575: 101-113.
5. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, et al. (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325: 1254-1257.
6. Spiegel S, Milstien S, (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407.
7. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH, (2004) G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92: 949-966.
8. Herr DR, Chun J, (2007) Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Current Drug Targets 8: 155-167.
9. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, et al. (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
10. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S, (2002) Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 281: 115-127.
11. Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, et al. (2005) Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett 579: 5313-5317.
12. Doll F, Pfeilschifter J, Huwiler A, (2005) The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim Biophys Acta 1738: 72-81.
13. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, et al. (2002) Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 277: 10539-10546.
14. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, et al. (2007) Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 117: 2506-2516.
15. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, et al. (2000) Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961.
16. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, et al. (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225-238.
17. Goetzl EJ, Dolezalova H, Kong Y, Zeng L, (1999) Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res 59: 4732-4737.
18. Dolezalova H, Shankar G, Huang MC, Bikle DD, Goetzl EJ, (2003) Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate. J Cell Biochem 88: 732-743.
19. Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, et al. (2006) Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 130: 80-87.
20. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, et al. (2003) Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 278: 32841-32851.
21. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y, (2003) Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol 23 1534-1545.
22. Le Stunff H, Mikami A, Giussani P, Hobson JP, Jolly PS, et al. (2004) Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J Biol Chem 279: 34290-34297.
23. Martin JL, Lin MZ, McGowan EM, Baxter RC, (2009) Potentiation of growth factor signaling by insulin-like growth factor binding protein-3 in breast epithelial cells requires sphingosine kinase activity. Journal of Biological Chemistry.
24. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, et al. (2006) Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173: 301-310.
25. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, et al. (1999) Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99: 301-312.
26. Wang F, Van Brocklyn JR, Hobson JP, Movafagh S, Zukowska-Grojec Z, et al. (1999) Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis. J Biol Chem 274: 35343-35350.
27. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, et al. (2000) Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 348 Pt 1 71-76.
28. Paik JH, Chae S, Lee MJ, Thangada S, Hla T, (2001) Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem 276: 11830-11837.
29. Langlois S, Gingras D, Beliveau R, (2004) Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103: 3020-3028.
30. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, et al. (2004) The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 279: 29367-29373.
31. Fieber CB, Eldridge J, Taha TA, Obeid LM, Muise-Helmericks RC, (2006) Modulation of total Akt kinase by increased expression of a single isoform: requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells. Exp Cell Res 312: 1164-1173.
32. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, et al. (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. American Journal of Pathology 177: 2205-2215.
33. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, et al. (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452: 654-658.
34. Nixon GF, (2009) Sphingolipids in inflammation: pathological implications and potential therapeutic targets. British Journal of Pharmacology 158: 982-993.
35. Oz-Arslan D, Ruscher W, Myrtek D, Ziemer M, Jin Y, et al. (2006) IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. J Leukoc Biol 80: 287-297.
36. Czeloth N, Bernhardt G, Hofmann F, Genth H, Forster R, (2005) Sphingosine-1-phosphate mediates migration of mature dendritic cells. Journal of Immunology 175: 2960-2967.
37. Peters SL, Alewijnse AE, (2007) Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7: 186-192.
38. Roviezzo F, Brancaleone V, De Gruttola L, Vellecco V, Bucci M, et al. (2011) Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo. Journal of Pharmacology and Experimental Therapeutics.
39. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, et al. (2007) Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. American Journal of Respiratory Cell and Molecular Biology 37 222-231.
40. Singleton PA, Dudek SM, Ma SF, Garcia JG, (2006) Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. Journal of Biological Chemistry 281: 34381-34393.
41. Ruf W, Furlan-Freguia C, Niessen F, (2009) Vascular and dendritic cell coagulation signaling in sepsis progression. J Thromb Haemost 7 (Suppl 1): 118-121.
42. Ferguson SS, Caron MG, (2004) Green fluorescent protein-tagged beta-arrestin translocation as a measure of G protein-coupled receptor activation. Methods Mol Biol 237: 121-126.
43. Licht T, Tsirulnikov L, Reuveni H, Yarnitzky T, Ben-Sasson SA, (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102: 2099-2107.
44. Kon J, Sato K, Watanabe T, Tomura H, Kuwabara A, et al. (1999) Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. Journal of Biological Chemistry 274: 23940-23947.
45. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, et al. (2002) Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem 277: 25152-25159. Epub 22002 May 25152.
46. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, et al. (2001) Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem 276: 33697-33704. Epub 32001 Jul 33696.
47. Jacobs E, Watson SA, Michaeli D, Ellis IO, Robertson JF, (1999) Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. British Journal of Cancer 80: 352-359.
48. Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, et al. (2007) Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 6: 891-897.
49. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, et al. (2009) Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118: 33-43.
50. Chun J, Brinkmann V, (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12: 213-228.
51. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, et al. (2006) Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. Journal of Cell Biology 173: 301-310.
52. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073-1083.
53. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140.
54. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, et al. (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231.
55. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, et al. (2010) FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Research 70: 8651-8661.